Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-RSV01 in RSV-infected lung transplant patients
NCT01065935Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2010
- Primary completion
- Apr 2012
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of asvasiran in respiratory syncytial virus infection (RSV), sponsored by Alnylam Pharmaceuticals. Started Feb 2010; status: completed.
02
Drugs
asvasiran
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT01065935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01065935.